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Abstract We report a novel non-viral system for transfecting
human immature hematopoietic cells in vitro. Epstein-Barr virus
(EBV)-based episomal vectors carrying human adenosine de-
aminase (ADA) gene cDNA were transfected by electroporation
into human peripheral blood (PB) CD34+ cells. The transgene-
specific mRNA were detected from 37 to 100% of CFU-c (colony
forming unit in culture) colonies derived from the transfected
cells. A two-fold increase in enzyme activity was also found.
These results indicate the successful transfer and expression of
genes in human immature hematopoietic cells using the EBV-
based episomal vector system.
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1. Introduction
An e⁄cient gene transfer system for human hematopoietic
progenitor cells is required for gene therapy of hematopoietic
diseases. Many of the systems currently available utilize the
replication-incompetent retroviral vectors, while other re-
combinant viral vectors such as lentiviral vectors are also
being developed [1,2]. We focused on plasmid vectors; if hem-
atopoietic progenitor cells can be transfected with plasmid
vectors by a simple method like electroporation, the system
may be of practical value, so that gene therapy will become
routine clinical work in the future. We engaged the Epstein-
Barr virus (EBV)-based episomal vector, the plasmid vector
carrying the EBV nuclear antigen (EBNA)-1 gene and the
origin of plasmid replication (oriP), because this vector is
very e¡ective in transfecting human cells [3^5].
We have previously shown that the gene transfer/expression
e⁄ciency with the EBV-based episomal vectors was extremely
high, when the plasmids were transfected by electroporation
into lymphoid cell lines of human origin [6,7]. Various human
primary cells were also successfully transfected with the EBV-
based episomal vectors, by combining the plasmids with cat-
ionic liposome or hemagglutinating virus of Japan (HVJ) lipo-
some [8]. Here, we transferred adenosine deaminase (ADA)
gene into human peripheral blood (PB) CD34 cells in vitro
and estimated the transfection e⁄ciency.
2. Materials and methods
2.1. Plasmid vectors
The ADA gene-expression vectors (Fig. 1A) are composed of (i) the
human ADA gene cDNA located between the SRK promoter [9] and
the SV40 poly(A) additional signal; (ii) EBV oriP [3]; (iii) the EBV
EBNA1 gene [3] under the control of SRK promoter (pSES.ADA),
cytomegalovirus (CMV) promoter (pCES.ADA), chicken L-actin pro-
moter (pLES.ADA), CAG promoter [10] (pCAGES.ADA) or SV40
promoter (pSVES.ADA); and (iv) the ampicillin resistant gene and
the replication origin for E. coli. Another plasmid, pSES.CD8K [8],
possesses murine CD8K cDNA located downstream of the SRK pro-
moter (Fig. 1B).
2.2. PB CD34+ cells
Prior to the experiments, informed consent was obtained from 6 pa-
tients with malignancies (3 with non-Hodgkin’s lymphoma, 1 with
ALL (L2), 1 with small-cell lung cancer and 1 with Ewing’s sarcoma)
in complete remission. The cancer cells from all the patients were
CD343 (data not shown). The PB CD34 cells were obtained from
these patients as described [11^13]. Brie£y, patients were administered
subcutaneously with 5 Wg/kg of recombinant human G-CSF (granu-
locyte-colony stimulating factor) after high dose chemotherapy. Using
a CS-3000 blood cell separator (Fenwal, Deer¢eld, IL, USA), periph-
eral mononuclear cells were collected on 2^3 consecutive days during
the recovery phase from myelosuppression. The CD34 cells were
enriched using a magnetic cell sorting system (Miltenyi Biotech, Glad-
bach, Germany). More than 95% of the recovered cells were positive
for CD34.
2.3. Transfection, cell culture and RT-PCR analysis
Electroporation was performed as described previously [7] using a
Gene Pulser apparatus (Bio-Rad). After the transfection, the cells
were cultured in Iscove’s modi¢ed Dulbecco’s medium (IMDM) (Gib-
co-BRL, Grand Island, NY, USA) supplemented with 10% FCS,
10 Wg/ml of IL-3 (Gibco-BRL), 10 U/ml of IL-6 (Gibco-BRL) and
10 U/ml of stem cell factor (SCF) (Pepro Tech, Rocky Hill, NJ,
USA). Three, 6 or 13 days later, RNA was extracted and treated
with DNase I (Boehringer Mannheim, Germany), followed by reverse
transcription (RT) by Superscript II (Gibco-BRL). PCR was then
performed using human L-actin gene-speci¢c sense (5P-GTGCT-
ATCCCTGTACGCCTC-3P) and antisense (5P-AGTCCGCCTAGA-
AGCATTTG-3P) primers, murine CD8K gene-speci¢c sense (5P-TCG-
CTGAACCTGCTGCTGCT-3P) and antisense (5P-GTTGTAGC-
TTCCTGGCGGTG-3P) primers, or a combination of human ADA
gene-speci¢c sense (5P-TTACTGATGCTCCTGACCCC-3P) and SV40
poly(A)-speci¢c antisense (5P-GCAGTAGCCTCATCATCACT-3P)
primers. The reactions were performed for 30 cycles (92‡C for 1 min,
56‡C for 1 min and 72‡C for 2 min) and the PCR products were
electrophoresed on a 1.5% agarose gel and stained by ethidium
bromide.
2.4. PCR analysis from colony forming unit in culture (CFU-c)
colonies
Cells were seeded into 0.9% methylcellulose/IMDM supplemented
with 3 U/ml of erythropoietin, 10 ng/ml of IL-3, 10 ng/ml of GM-CSF
and 50 ng/ml of SCF. Sixteen days later, single CFU-c colonies were
picked up under a phase-contrast microscope, heated for 1 min at
90‡C and then incubated for 1 h at 37‡C with 10 U of DNase I
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(Boehringer) and 0.3 U of RNase inhibitor (Toyobo, Osaka, Japan).
After boiling, cDNA synthesis and a ¢rst PCR were performed with
the De¢nitive RT-PCR KIT (Biotech International), using murine
CD8K gene-speci¢c sense (5P-TCGCTGAACCTGCTGCTGCT-3P)
and antisense (5P-GTTGTAGCTTCCTGGCGGTG-3P) primers, or
a combination of ADA gene-speci¢c sense (5P-TTACTGATGCTCC-
TGACCCC-3P) and SV40 poly(A)-speci¢c antisense (5P-GCAGTAG-
CCTCATCATCACT-3P) primers. The reactions were performed with
a thermal cycler (TaKaRa, Tokyo, Japan) using the following cycle
pro¢les: 60‡C for 30 min, 94‡C for 2 min and 60‡C for 1 min, fol-
lowed by 60 cycles of 94‡C for 1 min, 60‡C for 1 min and 72‡C for
1 min. The PCR products were subjected to a second PCR with Ex
Taq DNA polymerase (TaKaRa) using murine CD8K gene-speci¢c
sense (5P-CACAGGCACCCGAACTCCGA-3P) and antisense (5P-TC-
TGACTAGCGGCCTGGGAC-3P) primers, or a combination of
ADA gene-speci¢c sense (5P-GTCCATTTCTGCACACACGT-3P)
and SV40 poly(A)-speci¢c antisense (5P-TGCTCCCATTCATCA-
GTTCC-3P) primers.
2.5. Enzyme assay
The ADA enzyme assay was performed as described [14,15] with
slight modi¢cations. Brie£y, aliquots of cell lysate were added to a
reaction mixture (100 mM Tris-HCl, pH 7.5, 500 WM adenosine, 33
WM [8-14C]adenosine (2.2 GBq/mmol)) in a total volume of 20 Wl.
After incubation at 37‡C for 30 min, the reactions were subjected to
descending paper chromatography. Radioactive counts in adenosine,
inosine and hypoxanthine were measured by a BAS 2000 imaging
analyzer (Fuji Photo Film, Tokyo, Japan) and the amount of inosine
and hypoxanthine generated from adenosine (pmol) was calculated by
the formula: 104 (pmol)U(I+H)/(I+H+A), where 104 pmol is the
amount of adenosine initially added to the reaction and I, H, and
A are the radioactivities for inosine, hypoxanthine and adenosine,
respectively.
3. Results
3.1. Expression of the marker gene mRNA in CD34+
cells transfected with EBV-episomal vector
We ¢rst examined whether CD34 cells transfected with the
EBV-based vectors expressed the transgene mRNA. RNA was
extracted from CD34 cells which had been transfected with
pSES.CD8K and cultured for 3 days with IL-3, IL-6 and SCF.
RT-PCR was performed using mouse CD8K gene-speci¢c
primers. As shown in Fig. 2A, the transfected cells expressed
the marker gene mRNA on day 3 post-transfection. The in-
tensities of the bands correlated with the voltage at which the
cells were pulsed. In contrast, no expression was observed in
cells which had been given the plasmid DNA but pulsed. To
investigate if the expression would continue for longer culture
periods, CD34 cells were transfected with pSES.ADA, pCA-
GES.ADA or pSES.CD8K and cultured for 6 or 13 days.
Cells transfected with pSES.ADA or pCAGES.ADA ex-
pressed the transgene mRNA on both day 6 and 13, while
non-transfected or pSES.CD8K-transfected cells showed no
evidence of mRNA expression (Fig. 2B). These results indi-
cated the successful transfection, expression and maintenance
of the marker genes in the CD34 cells.
3.2. Transfection e⁄ciency into CFU-c by the EBV-based
episomal vectors
Next we investigated whether immature cells with colony
forming activity could be transfected using this system. PB
CD34 cells transfected with pSES.ADA or pSES.CD8K
were allowed to form CFU-c colonies and single CFU-c col-
onies were picked up and individually analyzed to estimate the
transfection e⁄ciency into each type of CFU-c. Fig. 2C shows
the results of a representative experiment. In this case (when
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Fig. 1. Plasmids used in this study. Maps of pXES.ADA (A) and
pSES.CD8K (B) are shown. Prom: promoter; polyA: SV40 poly(A)
additional signal.
Table 1
RT-PCR analyses of single colonies derived from transfected PB CD34 cells
Experiment Plasmid Primers (sense/antisense) Colonies
CFU-GM CFU-mix BFU-e CFU-Mk
1 pSES.ADA ADA/SV40a 6/8b 3/8 3/8 NDc
CD8K/CD8Kd 0/8 0/8 0/8 ND
2 pSES.ADA ADA/SV40 6/8 4/8 4/8 ND
CD8K/CD8K 0/8 0/8 0/8 ND
3 pSES.ADA ADA/SV40 4/8 5/8 4/8 ND
CD8K/CD8K 0/8 0/8 0/8 ND
4 pSES.CD8K ADA/SV40 0/8 0/8 0/8 ND
CD8K/CD8K 8/8 4/8 3/8 ND
5 pSES.CD8K ADA/SV40 0/8 0/8 0/8 0/4
CD8K/CD8K 8/8 6/8 6/8 3/4
PB CD34 cells were transfected with indicated plasmids, and CFu-c colonies derived from the cells were individually picked up and analyzed by
RT-PCR.
aThe combination of human ADA gene-speci¢c sense primer and SV40 poly(A) speci¢c antisense primer was used.
bNumber of positive colonies/number of colonies tested.
cND: Not determined.
dThe mouse CD8K gene speci¢c sense and antisense primers were used.
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pSES.CD8K was transfected), the murine CD8K mRNA was
detected in 8 out of 8 GM-CSF colonies, 6 out of 8 CFU-mix
colonies, 6 out of 8 BFU-e colonies and 3 out of 4 CFU-Mk
colonies. Similar results were obtained from 4 independent
experiments, as summarized in Table 1. No band was seen
when colonies derived from the pSES.ADA-transfected
PBSC were analyzed with murine CD8K-speci¢c primers,
and vice versa. To con¢rm the speci¢city of the PCR, we
also analyzed the CFU-c colonies derived from PB CD34
cells which had been mixed with pSES.ADA but pulsed. We
did not detect any band in all samples tested (the representa-
tive data are shown in Fig. 2D).
3.3. Elevation in ADA activities in PB CD34+ cells transfected
with the EBV-based episomal vectors carrying the ADA
gene expression units
To analyze the transgene product at the protein level, we
measured the ADA enzyme activity of PB CD34 cells trans-
fected with pXES.ADA. As shown in Fig. 3A and B, the
ADA activity of the pSES.ADA-transfected cells was 1.4^2
times higher than that of the pSES.CD8K-transfected cells
(endogenous ADA activity). The degree of the elevation de-
pended on the vector constructs, suggesting the importance of
a promoter/enhancer for EBNA1 gene in transfection/expres-
sion e⁄ciency (Fig. 3B). The elevation in enzyme activity was
also observed in pooled CFU-c colonies derived from PB
CD34 cells transfected with pSES.ADA (Fig. 3C).
4. Discussion
In the present study, we found that human immature hem-
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Fig. 3. ADA activity of the transfected cells. PB CD34 cells were
transfected with pSES.ADA (open squares in A and C), pSES.CD8K
(closed circles in A and C), or indicated plasmids (in B). Cells cul-
tured for 3 days (A and B) or pooled CFU-c colonies derived from
the transfected cells (C) were lysed and ADA enzyme activities were
assayed as described in Section 2.
Fig. 2. RT-PCR analyses of transfected PB CD34 cells and single CFU-c colonies derived from them. A: PB CD34 cells were mixed with
pSES.CD8K and pulsed at 410 V (lanes 2 and 6), 370 V (lanes 3 and 7), 330 V (lanes 4 and 8) or, as control, 0 V (lanes 1 and 5). After 3 days
of culture, RNA was extracted and subjected to DNase I treatment. RT-PCR was performed with primers speci¢c for human L-actin gene
(lanes 1^4) or murine CD8K gene (lanes 5^8). B: Cells were mixed with pSES.ADA (lanes 1, 4 and 6), pCAGES.ADA (lanes 2 and 7) or
pSES.CD8K (lanes 3, 5, 8 and 9), and pulsed at 410 V (lanes 1^3, and 6^8) or 0 V (lanes 4, 5 and 9). After 6 (lanes 1^5) or 13 (lanes 6^9)
days of culture, RNA extraction, DNase I treatment and RT-PCR were performed. ADA gene-speci¢c sense primer and SV40 poly(A)-speci¢c
antisense primer were used. C: PB CD34 were transfected with pSES.CD8K and allowed to form CFU-c colonies. Sixteen days later, single
CFU-c colonies were picked up and after extraction and DNase I treatment RT-PCR was performed using murine CD8K gene-speci¢c primers.
Each lane represents single colonies of the indicated type. D: PB CD34 were mixed with pSES.ADA and pulsed at 410 V (right 8 lanes) or
0 V (left 8 lanes). Sixteen days later, single CFU-mix colonies were picked up and after extraction and DNase I treatment RT-PCR was per-
formed with ADA gene-speci¢c sense primer and SV40 poly(A)-speci¢c antisense primer. Each lane represents single colonies. P : PX174 DNA,
HaeIII digested; L: 123-bp DNA ladder.
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atopoietic cells could be successfully transfected in vitro with
the EBV-based vector system. The transfection e⁄ciency to
CFU-c was estimated to be more than 37%. The expression of
the transgene product was con¢rmed by the elevated ADA
activity.
We transfected PB CD34 cells by electroporation because
it is a safe, easy, inexpensive and highly reproducible techni-
que and thus well suited to ex vivo gene transfer. The cell
viability is 50^70% after the electroporation and the number
of CFU-c decreased in parallel (data not shown). Practically,
the number of PB progenitor cells harvested from a donor is
usually much higher than that transplanted to a recipient
[16,17]. Recently, we have combined the EBV vector with
other gene delivery systems, i.e. cationic liposome, HVJ lipo-
some, and succeeded in transfecting human bone marrow
cells [8]. This may indicate that the EBV episomal vector in
combination with various delivery vehicles could be a useful
tool for gene transfer into human hematopoietic cells.
Compared to bone marrow (BM) transplantation, PB stem
cell transplantation has some advantages: ease of collection,
rapid engraftment and less possibility of tumor cell contami-
nation in the graft [16,18,19]. Thus, PB progenitor cells may
be an ideal target for gene therapy for hematopoietic as well
as malignant diseases.
It is known that the PB CD34 cells contain higher pro-
portion of lineage committed cells than BM CD34 cells do.
More than 98% of PB CD34 cells prepared by our hands
expressed CD38, as revealed by 2-color £ow cytometric anal-
ysis (data not shown). We are planning to perform LTC-IC
assay to examine if cells more immature than CFU-c can also
be transfected by our system.
Recently, it has been revealed that the hematopoietic stem
cells with long term repopulating activity belong to the
CD343 population [20^23]. Thus, this population should be
regarded as the target for gene transfer. We are planning to
transfect CD34 positive and negative cells and transplant
them into NOD (non-obese diabetes)/SCID (severe combined
immunode¢ciency) mice, to examine the in vivo expression
and long term maintenance of the transferred gene [23].
The EBV-based vectors are plasmid vectors, producing no
infectious virus particles. The EBNA1 is the only viral protein
encoded by the plasmid. Although the EBV is an oncogenic
virus, it is reported that EBNA2, LMP (latent membrane
protein)1 and other latent gene products play essential roles
in B-cell transformation, while EBNA1 has no transformation
activity [24^28]. On the other hand, it is well known that
EBNA1 escapes recognition by host immune systems [29^
32]. Thus, the EBV-based episomal vectors may be neither
oncogenic nor immunogenic, although their safety must be
con¢rmed by in vivo experiments.
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